Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology DrugsNews DeskMay 8, 20260 Odyssey Therapeutics continues the immunology journey of serial biotech entrepreneur Gary Glick, who is pursuing drugs that could offer advantages…